In the long run (starting at one year after FDA ap

In the long run (starting at one year after FDA approval) and onwards, keeping the HIV indication and partnering for commercialization will mean much bigger profits for Cytodyn and full funding for cancer and other indications out of revenue.

Selling out for $50 million and 10% means we'll have immediate funding to jumpstart trials which will probably last 16 months at most. After that we'll be running on maximum $100 million a year at most. Enough to push some trials forward but not all.

With a partnership and us getting 40%, within the first year we'll see $200 million at most, but $400 million a year thereafter. Enough to fund all trials and return a profit.

If you're looking at selling soon for a smaller profit then selling the indication is best. Longer term a partnership is a much better deal.